Satoshi Hara

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi et al. · JAMA Oncology · 2021 · 185 citations · Full text

Medicine, Oncology, Pharmacology +16

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study

Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka et al. · Lung Cancer · 2018 · 150 citations

Medicine, Oncology, Pharmacology +11

New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases

Kazunori Yamada, Motohisa Yamamoto, Takako Saeki et al. · Arthritis Research & Therapy · 2017 · 148 citations · Full text

Life Sciences, Pathology, Autoimmunity +7

Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy

Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka et al. · Journal of Thoracic Oncology · 2018 · 121 citations

Medicine, Oncology, Pharmacotherapy +8

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya et al. · European Journal of Cancer · 2021 · 89 citations

Medicine, Oncology, Pharmacology +12